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Abstract 
Background: Spinal metastases of patients with advanced stage lung cancer are an 
important target for palliative therapy, because their incidence is high, and they often 
cause severe symptoms and worsen the quality of life. Surgery is one of the most 
effective treatment options, but the indication of surgery is unclear as the procedure is 
invasive and patients with spinal metastasis have a rather short life expectancy. 
Furthermore, there have been few studies that have focused on lung cancer with poor 
prognosis.  
Methods: We reviewed all of the cases of lung cancer from January 1999 to July 2007 in 
the Department of Respiratory Medicine, Kyoto University Hospital, Japan. Thirteen 
patients with metastatic spinal tumor of lung cancer underwent surgery, and all of them 
had a poor performance status score (3 or 4).  
Results: Neurological improvement by at least 1 Frankel grade was seen in 10 of 14 cases 
(71%). Improvement of the movement capacity was noted in 9 of 14 cases (64%), and 
pain improvement was noted in 12 of 14 (86%). Median postoperative survival was 5 
months (1–25 months). In particular, the group with a good postoperative performance 
status score (0–2) was shown to have a better median postoperative survival of 13 
months.   
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Conclusions: Surgical treatment for symptomatic metastatic spinal tumor of lung cancer 
can improve quality of life in a substantially high percentage of patients. Surgery should 
be considered even if preoperative performance status is poor. 
Introduction 
Worldwide, lung cancer remains the leading cause of cancer death in both men and 
women. Fifty percent of the patients have distant metastasis at the time of diagnosis. 
Spinal metastasis in patients with all types of cancer combined varies between 30 and 
70%, and is most frequent in patients with lung cancer (60%). All these patients are at risk 
of developing symptomatic spinal cord compression [1] with an incidence of 5–14% [2]. 
Spinal metastasis often causes severe pain and neurologic dysfunction, and may 
exacerbate the prognosis and quality of life of patients. Thus, metastatic spinal disease is 
one of the important therapeutic targets in the management of patients with advanced 
cancer. 
Metastatic spinal tumor is treated by surgery, radiotherapy or chemotherapy as well as 
more conservative palliative treatments such as opioids, non-steroid anti-inflammatory 
agents or corticosteroid. Surgical procedures often contribute to pain relief, neurological 
recovery and mechanical stability of the site of metastasis. It can stop rapidly progressive 
paralysis and recover neurological symptoms in some cases in which such recovery is not 
attainable with other kinds of interventions. However, the criteria for surgical indication 
are not clear. Because of its invasiveness, surgery is indicated only if a relatively long 
survival is expected and if the anticipated improvement in quality of life outweighs the 
risks. 
There have been some studies on the outcome of surgical treatment of metastatic 
spinal disease from various cancers [3, 4]. The prognosis of patients with spinal metastasis 
and surgical treatment is relatively good, when all kinds of cancers are considered 
together. Tatsui et al. [5] reported that survival rates were the lowest in patients with lung 
cancer. Moreover, it was reported that patients with lung cancer and melanoma had the 
poorest prognosis in a series of 76 patients with various cancers [1]. However, there have 
been a few studies that have focused on lung cancer. Chen et al. [6] reported good 
symptom relief for metastatic spinal disease of lung cancer, and 18 patients (58.1%) had a 
relatively good Eastern Cooperative Oncology Group (ECOG) performance status (PS) 
score of 0 or 1. In the present study, including patients with poor performance status, we 
studied the usefulness of surgery in symptomatic spinal metastasis of lung cancer. 
Patients and Methods 
We retrospectively reviewed all records of patients with lung cancer in the Department of 
Respiratory Medicine, Kyoto University Hospital, Japan, from January 1999 to July 2007. There were 14 
patients who underwent surgery for metastatic spinal disease of lung cancer. Information was obtained 
from patient records, including age, pathological diagnosis, findings of spinal MRI and CT from the 
neck to the pelvis, ECOG PS, symptoms (paralysis, pain and movement capacity), pre- and 
postoperative movement capability, operative method, location of operation, pre- and postoperative 
prescription, duration from symptom appearance to operation, and postoperative complications and 
prognosis. 
To evaluate neurological status, we used the Frankel grading system [7] in the preoperative and 
postoperative periods. Activities of daily living (ADL) were classified into 3 categories: can walk 
independently, can move with wheel chair, and can not move. Pain was expressed as grade of  
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prescription necessary to control pain according to the World Health Organization Pain Relief Ladder 
(WHO Ladder). This evaluation was performed 1 month after operation. 
Results 
A total of 772 lung cancer patients were diagnosed or referred to the Department of 
Respiratory Medicine, Kyoto University Hospital, from January 1999 to July 2007, and 14 
(1.7%) underwent surgery for metastatic spinal disease. The indications for surgery 
consisted of intractable pain or neurological deterioration. Surgery was not considered if 
the extent of the metastatic disease precluded adequate stabilization with segmental 
instrumentation and if the expected survival was <3 months.  
The baseline characteristics of all patients at surgery are summarized in table 1. The 
median age was 63.8 years (range 54–78 years). There were 8 male and 5 female patients. 
The most common histological type was adenocarcinoma. The most common site of 
involvement, in 9 patients, was the thoracic spine. Eleven patients underwent spinal 
decompression by laminectomy and posterior spinal fusion, and 1 underwent spinal 
decompression and anterior spinal fusion. There was 1 postoperative complication and 
recovery without reoperation. The maximum recovery lasted until the end of life in all 
patients. Thirteen of 14 cases were treated with chemotherapy and/or radiotherapy before 
or after surgery. 
The neurological outcome after surgery is shown in fig. 1 and table 2. More than 1 
grade of improvement in Frankel’s scale was noted in 10 of 14 cases (71%). Three cases 
graded B did not show improvement after surgery. None became worse after surgery. 
We also estimated ADL as indicated in the Patients and Methods section. 
Improvement in ADL was noted in 9 of 14 cases (64%) (fig. 2). ECOG PS before the 
symptoms caused by spinal metastasis was a mean of 2.29 (PS1, 2; PS2, 6; PS3, 6). PS 
immediately before surgery was a mean of 3.61 (PS3, 5; PS4, 8). After surgery, PS 
recovered to a mean of 1.29 (PS1, 5; PS2, 5; PS3, 2; PS4, 2). PS of 2 patients with PS4 did 
not change, and none of the cases worsened after surgery (table 2). 
Symptoms of spinal pain were reported by all patients before surgery, and pain grade 
was 2 or 3 on the WHO Ladder. After surgery, improvements of more than 1 grade were 
noted in 12 of 14 cases (86%), and 6 of these became grade 0, with complete relief of pain 
(fig. 3). 
Median postoperative survival was 5 months (1–24 months). One patient was still alive 
at the time of this study. The group with a good postoperative PS (0–2) was shown to have 
better median postoperative survival than that with a poor postoperative PS (3–4) (table 
3). 
Discussion 
Prognosis of patients with extensive lung cancer is still poor even with the 
development of chemotherapeutic drugs. Thus, symptom relief and maintenance of 
quality of life are important aims of medical intervention in patients with advanced-stage 
lung cancer, especially after failure of the initial therapy. Lung cancer frequently develops 
metastasis to the spine, and it often leads to compression fracture or spinal dysfunction. 
Once compression fracture or spinal dysfunction has occurred, the quality of life of the 
patient deteriorates severely. Therefore, spinal metastasis is an important target in  
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supportive care. In recent years, surgical treatment has been indicated for patients with 
symptoms of metastatic spinal tumors. Surgical procedures can immediately improve 
pain, neurological dysfunction, mechanical stability, and quality of life, although it is the 
most invasive treatment for patients with advanced lung cancer, and the criteria for 
surgical treatment of metastatic spinal tumor are still not clear. We reviewed our series of 
patients to investigate the efficacy of surgical treatment. 
The indication of surgery for metastatic spinal disease is still controversial. The life 
expectancy is one of the important factors to select the treatment modality [4, 8], and the 
prognosis of the patients with metastatic spine tumors is related to the primary site of 
malignancy [9]. Tokuhashi et al. [8] studied 246 patients with metastatic spinal tumors 
and proposed scoring systems to evaluate prognosis and the suitability of the subsequent 
treatment strategy [2, 8]. In their series, lung cancer belonged to the poor prognosis 
groups, and they concluded that lung cancer is a negative factor for indication of surgery. 
Weigel et al. [1] also stated that survival of patients with lung cancer is the poorest (2.1 
months) among all patients with solid cancer in their series. These reports may indicate 
that surgical indication of patients with lung cancer needs to be discussed separately from 
other solid cancers with a relatively longer life expectancy. 
According to the past few reports which studied patients with lung cancer, an expected 
survival time in a range of 3 to 6 months has been used as a criterion for choosing surgical 
treatment. In 1995, Sundaresan et al. [10] showed that the median survival was 6 months 
after surgical treatment for spinal metastasis. In the study of Chen et al. [10] in 2007, 
median survival after surgery was 8.8 months, and 10 of 31 patients survived more than 1 
year. The survival in other series ranged from 1.5 to 9.9 months [1, 10–12]. Ogihara et al. 
[15] found that the prognostic factors of patients with spinal metastases from non-small 
cell lung cancer were PS, serum calcium, and serum albumin, and that PS was a 
significant factor for survival in the postoperative period among the operated patients. 
The PS of patients involved in the current study was 3 or 4, which is poorer than in 
previous reports. However, postoperative median survival in the current study was 5 
months (1–25 months), and it was compatible with those of previous reports. 
Tanaka et al. [13] studied 100 cases of metastatic spinal tumors with various origins, 
and they found that preoperative pain and paralysis improved by 88.0 and 53%, 
respectively, and that quality of life score improved by 53%. Bach et al. [9] reported 102 
cases of metastatic spinal cord compression secondary to lung cancer. Ninety-five percent 
of patients were able to walk after surgery. Sundaresan et al. [10] reported that 19 of 25 
patients regained the ability to walk. Chen et al. [6] studied 31 patients with lung cancer 
and spinal metastasis and showed that 23 regained the ability to walk after surgery and 
that neurological improvement was noted in 25. In our study, after surgical treatment, 
neurological improvement, improvement of movement capacity and improvement in 
pain was 69, 62 and 84%, respectively. Performance status scores also improved in 9 of 13 
patients. These results show that, in advanced lung cancer with spinal metastases, 
improvement of symptoms by spinal surgery can be expected in a substantially high 
percentage of patients. 
In the current study, the group with a good postoperative PS (1 or 2) was shown to 
have a better median postoperative survival of 13 months, compared with 3 months in the 
group with a poor PS (3 or 4). Recovery of PS almost correlated with improvement of 
paralysis and ambulation. Commonly, it takes about 1 month for the patient to recover to 
the best postoperative condition and the patient suffers from degradation of the general 
condition and limitation of ADL for 1 month or so until death. Median postoperative 
survival was 5 months (1–24 months) in this series. It is suspected that the beneficial  
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period to the patients was less than 3 months in this series. Some authors have suggested 
that symptoms have no impact on survival in patients with spinal metastases [4, 14], and 
Hosono et al. [11] reported that walking ability is not a prognostic factor in patients with 
spinal metastases. However, other authors [12, 15, 16] have suggested that postoperative 
ambulation ability is associated with longer survival after surgery, even in patients with 
lung cancer. In the present study, postoperative but not preoperative PS was significant 
for postoperative survival time. 
Postoperative complications are another important factor in selecting treatment 
modality. In our study, 1 (7.7%) patient had postoperative infection. None of the patients 
died in the immediate postoperative period. Previous reports showed that complications 
occurred in a range from 13 to 25.8% [1, 3, 7]. Chen et al. [6] and Weigel et al. [1] 
reported that operation-related death occurred in 1 (3.2%) and 2 (2.3%) patients, 
respectively. Other minor complications reported were wound infection, wound 
dehiscence, hoarseness and respiratory insufficiency. In recent studies, there was no case 
of intraoperative mortality. 
The limitations of our study are a relatively small number of patients studied and lack 
of a control group. However, lung cancer is often thought to be one of the poorest 
prognosis groups among solid cancers. Surgical treatment of metastatic spinal disease 
might be considered to improve quality of life and recovery of independent ambulation. 
Further prospective studies are needed on metastatic spinal tumor of lung cancer to 
confirm the utility of the surgical treatment of metastatic spinal disease especially 
compared with radiation therapy. 
Conclusion 
Surgical treatment for symptomatic metastatic spinal tumor of lung cancer can 
improve quality of life in a substantially high percentage of patients. Surgery should be 
considered even if preoperative performance status is poor. 
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Table 1. Patient characteristics and treatments 
Other treatment    Case Age   
(sex) 
Pathology Location  Surgical   
approach 
pre- 
operative 
post- 
operative 
 
Other metastases 
01  57 (F)  Adenocarcinoma  Th5, 8  Posterior  CT  RT, gefitinib    Th11, L1, liver, ribs 
02  75 (F)  Adenocarcinoma  Th7–11  Posterior  –  RT    Liver, adrenal gland 
03  50 (F)  Adenocarcinoma  L1, 3  Posterior  RT  CT    Femoral bone 
04  63 (M)  Adenocarcinoma  Th9–11  Posterior  –   CRT    Th1, brain, pericardial effusion
05  59 (M)  Adenocarcinoma  C5, 6  Laminectomy  RT  CT, gefitinib    Th1, 2, ribs, femoral bone 
06  60 (M)  Adenocarcinoma  Th4, 5  Posterior  CRT  Gefitinib    Adrenal gland 
07 65  (M)  Adenocarcinoma  Th6–8  Posterior  CRT  CT   Esophagus 
08 65  (M)  Adenocarcinoma  L1  Posterior  –  RT   – 
09 62  (M)  NSCLC  Th4  Posterior  CRT  –   Brain 
10 54  (M)  Squamous  cell 
carcinoma 
Th2 Posterior –  CRT    Pleural  effusion 
11 73  (F)  Squamous  cell 
carcinoma 
Th11, 12  Posterior  –  RT    Th2 
12  72 (M)  SCLC   Th11  Posterior  –  CRT    Th8–L3, pleural effusion 
13  75 (F)  SCLC  C4–6  Anterior  –  –    Pleural effusion 
14 78  (M)  SCLC  Th2–8  Anterior  CT  CT   Brain 
The table shows the baseline characteristics of all patients who underwent surgery for metastatic spinal disease of lung 
cancer. The most common histological type was adenocarcinoma, and the most common site of involvement was the 
thoracic spine. CT = Chemotherapy; RT = radiotherapy; CRT = chemo-radiotherapy; SCLC = small cell lung cancer; 
NSCLC = non-small cell lung cancer. 
 
 
Table 2. Preoperative and postoperative symptoms and outcomes 
PS Paralysis   
(Frankel grade) 
Improvement      Case 
pre  post  pre  post   pain  ADL  
Post- 
operative 
complication 
Post-
operative 
survival 
(months) 
01  4  2   C  D   +  –   –  04 
02  4  3   A  C   +  –   –  05 
03  4  1   D  E   +  +   –  24 
04  3  2   B  D   +  +   –  13 
05  3  1   C  E   +  +   –  16 
06  3  2   D  E   +  +   –  04 
07  3  2   E  E   +  +   –  03 
08  4  1   D  E   +  +   –  >3 
09  4  4   B  B   +  –   +  03 
10  3  1   C  E   +  +   –  25 
11  4  3   B  B   –  –   –  02 
12  4  2   B  C   +  +   –  05 
13  4  4   B  B   –  –   –  01 
14  3  1   C  D   +  +   –  08 
Preoperative PS was immediately before surgery. The explanation of the Frankel classification is shown 
in figure 1. There was 1 postoperative complication (wound infection). Improvements of at least 1 
symptom were noted in 12 of 14 cases (86%). 
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Table 3. Summary of patient outcomes 
Postoperative survival (mean), months  1–25 (5)   
Preoperative PS (immediately before surgery)  0–2 
3–4 
00 case 
14 cases 
Postoperative PS (mean survival months)  0–2 
3–4 
09 cases (13 months) 
05 cases (3 months) 
Improvement pain 
movement capacity 
paralysis 
12/14 cases (86%) 
09/14 cases (64%) 
10/14 cases (71%) 
Postoperative complication  wound infection  01 case 
The group with a good postoperative PS (0–2) was shown to have a better median postoperative 
survival than that with a poor postoperative PS (3–4). 
 
 
 
 
Fig. 1. Neurological status: preoperative and postoperative neurological evaluation using the Frankel 
classification. More than one grade of improvement in Frankel’s scale was noted in 10 of 14 cases 
(71%). 
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Fig. 2. Preoperative and postoperative movement capacity evaluation. We estimated ADL with 
movement capacity classified into 3 categories: can walk independently, can move with wheel chair, 
and can not move. Improvement in ADL was noted in 9 of 14 cases (64%). 
 
 
 
Fig. 3. Preoperative and postoperative pain evaluation using the WHO classification. Improvements of 
more than 1 grade were noted in 12 of 14 cases (86%). 
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